Valentino Bezzerri

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Hog1/p38 and ZAKα drive Shwachman-Diamond syndrome and provide targets to improve cell growth.

Hog1/p38 and ZAKα drive Shwachman-Diamond syndrome and provide targets to improve cell growth.

Journal: bioRxiv : the preprint server for biology

Published: February 13, 2026

The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.

The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.

Journal: Biomedicines

Published: October 10, 2025

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Beyond readthrough: ataluren restores mitochondrial function and reduces oxidative stress in FANCA-mutated cells via mTOR-DRP1 modulation.

Journal: Cell death discovery

Published: September 15, 2025

A Focus on Inflammatory and Bacterial Biomarkers in Secondary Peritonitis.

A Focus on Inflammatory and Bacterial Biomarkers in Secondary Peritonitis.

Journal: Cells

Published: August 26, 2025

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program.

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program.

Journal: Respiratory research

Published: August 19, 2025

Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.

Effects of GM1 ganglioside and its derivatives on ETI-rescued F508del-CFTR maturation and host-pathogen interactions in cystic fibrosis bronchial cells.

Journal: Glycoconjugate journal

Published: June 23, 2025

Beyond the bench: Revitalizing ataluren development for rare genetic disorders.

Beyond the bench: Revitalizing ataluren development for rare genetic disorders.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 29, 2025

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Journal: Journal of clinical medicine

Published: April 22, 2025

Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.

Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia.

Journal: Cell death discovery

Published: January 21, 2025

Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series.

Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series.

Journal: Nature communications

Published: January 20, 2025

Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome.

Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome.

Journal: The Journal of clinical investigation

Published: October 17, 2024

Constitutive systemic inflammation in Shwachman-Diamond Syndrome.

Constitutive systemic inflammation in Shwachman-Diamond Syndrome.

Journal: Molecular medicine (Cambridge, Mass.)

Published: October 09, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026